Glyconjugate Vaccines
US-2024382585-A1 · Nov 21, 2024 · US
Immunogenic compositions for use in pneumococcal vaccines
US10653764B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10653764-B2 |
| Application number | US-201615542802-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 5, 2016 |
| Priority date | Jan 15, 2015 |
| Publication date | May 19, 2020 |
| Grant date | May 19, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 9, while limiting the number of conjugates. The present invention thereforerelates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of inducing an immune response to S. pneumoniae serotypes 9N, 9A and/or 9L in a subject, comprising administering to the subject an immunologically effective amount of an immunogenic composition comprising at least one glycoconjugate from S. pneumoniae serotype 9V, wherein said immunogenic composition further comprises glycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 14, 18C, 19A, 19F, and 23F, and wherein said immunogenic composition further comprises at least one glycoconjugate S. pneumoniae serotype selected from serotype 8, 10A, 11A, 12F, 15B, 22F, and 33F. 2. A method according to claim 1 , wherein administration of said immunogenic composition to a subject elicits functional antibodies in said subject which are capable of killing S. pneumoniae serotype 9N, 9A and/or 9L as determined by in vitro opsonophagocytic assay (OPA). 3. A method according to claim 1 , wherein administration of said immunogenic composition to a subject elicits a titer of at least 1:8 against S. pneumoniae serotype 9N in at least 50% of the subjects as determined by in vitro opsonophagocytic killing assay (OPA).
Assignees
Inventors
Classifications
Drugs for disorders of the respiratory system · CPC title
- A61K39/092Primary
Streptococcus · CPC title
Haptens or antigens, bound to carriers · CPC title
Bacterial toxins · CPC title
Multivalent vaccine · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10653764B2 cover?
- An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 9, while limiting the number of conjugates. The present invention thereforerelates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccoc…
- Who is the assignee on this patent?
- Pfizer
- What technology area does this patent fall under?
- Primary CPC classification A61K39/092. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue May 19 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).